Earnings forecast lowered by 5-25% Q2'23e sales increase of 7% Focus on the ongoing stategic process...
Zoomability publicerade den 23 augusti 2023 bolagets delårsrapport för årets andra kvartal.
Redeye comments on AVTECHs announcement where it upsold Aventus Wind Services to Volotea.
Redeye comments on Scandion Oncology’s Q2 2023 report, and we judge that CORIST part 4 data in 2024e...
Recyctec publicerade den 22 augusti år 2023 bolagets delårsrapport för det andra kvartalet.
148% tillväxt i USA. OssDsigns nettoomsättning under Q2 uppgick till 24 mkr vilket motsvarar 92% til...
Inga överraskningar i rapporten Egetis rapport för det andra kvartalet var i linje med våra förväntn...
Redeye leaves its comments on Ortoma following its Q2 2023 report.
Redeye comments on Enviro’s Q2 2023 report, which held no surprises – as expected.
Redeye leaves a comment following Newbury’s announcement of a new strategic partnership with a globa...
Redeye comments the quarter was weaker than expected.
Redeye states that Modelon’s financial performance was above our projections on sales and profitabil...
Redeye updates its view of Egetis the Q2 report and recent events in the company.
Solteq’s Q2 results were quite weak and both revenue and profitability fell below our estimates.
Redeye comments on Artificial Solutions Q2’2023 report.
Redeye comments on Better Collective’s Q2-results which came in stronger than expected with solid pe...
Redeye resumes coverage after NeoDynamics’ rights issue.
Redeye provides an update on Kontigo Care following its Q2 2023 report.
Redeye comments on Ultimovacs’ Q2 2023 report, following a quarter in which the company’s share pric...
Redeye comments on Evaxion's second quarter report of 2023.
